Skip to main content
. 2022 Nov 3;2022:3125662. doi: 10.1155/2022/3125662

Figure 4.

Figure 4

Proportion of subjects with each of thirteen COVID-19 symptoms at day 1, 3, 7, 10, and 14 in the placebo and the hesperidin groups.